Domain Therapeutics

Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, associated to a target identification and drug discovery platform enable the Company to enhance the understanding of cancer and deliver innovative immunotherapies to patients. Domains...

Gpcr,immuno-oncology,cancer,immunotherapy,clinical research,drug development,precision research,precision medicine,clinical trials,cancer research,biotechnology,drug discovery,life sciences,biopharma,innovation,sustainability,cancer treatment,immunosuppression,patient-centered approach,immune system,cancer immunotherapy,tumor biology,tumor microenvironment,immunoresistance,clinical development,cancer-focused gpcr targets,biomarkers,soft mobility,green mobility,sustainable mobility,sustainable transportation,sustainable future,and inflammation

Domain therapeutics operates in the Pharmaceutical manufacturing industry.

Domain therapeutics's revenue is 11m - 100m

Domain therapeutics has 51 - 200 employees.